positive
EY & OPPI Report: India’s Pharma Exports Approach US$ 30 Billion as CRDMO Segment Grows
According to a joint report by EY Parthenon and OPPI, India’s pharmaceutical export value is nearing US$ 30 billion, driven by the growing contract research, development & manufacturing organisation (CRDMO) segment and expansion of global capability centres (GCCs).
The shift signals a move from generic drug production toward higher-value innovation, with digital-first strategies and deep-tech themes at the core. Analysts say regulatory agility, talent development and export market access will be crucial for the next phase of growth.
Tags:
- india
- pharma
Ey• By Harsh Ranjan
Explore:Mutual Fund Screening
positive
EY & OPPI Report: India’s Pharma Exports Approach US$ 30 Billion as CRDMO Segment Grows
According to a joint report by EY Parthenon and OPPI, India’s pharmaceutical export value is nearing US$ 30 billion, driven by the growing contract research, development & manufacturing organisation (CRDMO) segment and expansion of global capability centres (GCCs).
The shift signals a move from generic drug production toward higher-value innovation, with digital-first strategies and deep-tech themes at the core. Analysts say regulatory agility, talent development and export market access will be crucial for the next phase of growth.
Tags:
- india
- pharma
Ey• By Harsh Ranjan
Explore:Mutual Fund Screening
1 min read
77 words
India’s pharma exports are poised to hit US$ 30 bn as CRDMO and GCC growth accelerate its transition to higher-value innovation.
According to a joint report by EY Parthenon and OPPI, India’s pharmaceutical export value is nearing US$ 30 billion, driven by the growing contract research, development & manufacturing organisation (CRDMO) segment and expansion of global capability centres (GCCs).
The shift signals a move from generic drug production toward higher-value innovation, with digital-first strategies and deep-tech themes at the core. Analysts say regulatory agility, talent development and export market access will be crucial for the next phase of growth.
According to a joint report by EY Parthenon and OPPI, India’s pharmaceutical export value is nearing US$ 30 billion, driven by the growing contract research, development & manufacturing organisation (CRDMO) segment and expansion of global capability centres (GCCs).
The shift signals a move from generic drug production toward higher-value innovation, with digital-first strategies and deep-tech themes at the core. Analysts say regulatory agility, talent development and export market access will be crucial for the next phase of growth.
Tags:
- india
- pharma
- india
- pharma
- exports
- innovation
- crdmo